Next Article in Journal
Development of Laser Ionization Techniques for Evaluation of the Effect of Cancer Drugs Using Imaging Mass Spectrometry
Next Article in Special Issue
Clinical Significance of POU5F1P1 rs10505477 Polymorphism in Chinese Gastric Cancer Patients Receving Cisplatin-Based Chemotherapy after Surgical Resection
Previous Article in Journal
PSNO: Predicting Cysteine S-Nitrosylation Sites by Incorporating Various Sequence-Derived Features into the General Form of Chou’s PseAAC
Previous Article in Special Issue
Expression and Effects of High-Mobility Group Box 1 in Cervical Cancer
Int. J. Mol. Sci. 2014, 15(7), 11220-11233; doi:10.3390/ijms150711220
Article

The REST Gene Signature Predicts Drug Sensitivity in Neuroblastoma Cell Lines and Is Significantly Associated with Neuroblastoma Tumor Stage

1
, 2
, 3
, 4
, 1,* , 5
 and 1,*
Received: 23 April 2014; in revised form: 30 May 2014 / Accepted: 3 June 2014 / Published: 25 June 2014
View Full-Text   |   Download PDF [786 KB, uploaded 25 June 2014]   |   Browse Figures
Abstract: Neuroblastoma is the most common and deadly solid tumor in children, and there is currently no effective treatment available for neuroblastoma patients. The repressor element-1 silencing transcription (REST) factor has been found to play important roles in the regulation of neural differentiation and tumorigenesis. Recently, a REST signature consisting of downstream targets of REST has been reported to have clinical relevance in both breast cancer and glioblastoma. However it remains unclear how the REST signature works in neuroblastoma. Publicly available datasets were mined and bioinformatic approaches were used to investigate the utility of the REST signature in neuroblastoma with both preclinical and real patient data. The REST signature was found to be associated with drug sensitivity in neuroblastoma cell lines. Further, neuroblastoma patients with enhanced REST activity are significantly associated with higher clinical stages. Loss of heterozygosity on chromosome 11q23, which occurs in a large subset of high-risk neuroblastomas, tends to be correlated with high REST activity, with marginal significance. In conclusion, the REST signature has important implications for targeted therapy, and it is a prognostic factor in neuroblastoma patients.
Keywords: REST; neuron-restrictive silencer factor; neuroblastoma; tumor stage; drug sensitivity; chemotherapeutic target REST; neuron-restrictive silencer factor; neuroblastoma; tumor stage; drug sensitivity; chemotherapeutic target
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Liang, J.; Tong, P.; Zhao, W.; Li, Y.; Zhang, L.; Xia, Y.; Yu, Y. The REST Gene Signature Predicts Drug Sensitivity in Neuroblastoma Cell Lines and Is Significantly Associated with Neuroblastoma Tumor Stage. Int. J. Mol. Sci. 2014, 15, 11220-11233.

AMA Style

Liang J, Tong P, Zhao W, Li Y, Zhang L, Xia Y, Yu Y. The REST Gene Signature Predicts Drug Sensitivity in Neuroblastoma Cell Lines and Is Significantly Associated with Neuroblastoma Tumor Stage. International Journal of Molecular Sciences. 2014; 15(7):11220-11233.

Chicago/Turabian Style

Liang, Jianfeng; Tong, Pan; Zhao, Wanni; Li, Yaqiao; Zhang, Li; Xia, Ying; Yu, Yanbing. 2014. "The REST Gene Signature Predicts Drug Sensitivity in Neuroblastoma Cell Lines and Is Significantly Associated with Neuroblastoma Tumor Stage." Int. J. Mol. Sci. 15, no. 7: 11220-11233.


Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert